As the Australian market experiences a tentative rise, with shares initially pointing towards gains before potential afternoon reversals, investors are closely monitoring economic indicators and broader market sentiment that could impact small-cap stocks. In this environment, identifying high-growth tech stocks involves looking for companies that can navigate these fluctuations effectively while capitalizing on technological advancements and strategic opportunities in the sector.
Name
Revenue Growth
Earnings Growth
Growth Rating
Pureprofile
10.51%
37.56%
★★★★★☆
Pro Medicus
19.70%
21.18%
★★★★★☆
Kinatico
13.27%
42.29%
★★★★☆☆
Immutep
104.12%
46.46%
★★★★★☆
Clinuvel Pharmaceuticals
22.02%
23.88%
★★★★★☆
BlinkLab
104.90%
101.40%
★★★★★★
Wrkr
52.49%
88.00%
★★★★★★
Artrya
50.54%
61.25%
★★★★★☆
PYC Therapeutics
10.34%
24.39%
★★★★★☆
FINEOS Corporation Holdings
9.22%
57.85%
★★★★☆☆
Click here to see the full list of 23 stocks from our ASX High Growth Tech and AI Stocks screener.
Let’s explore several standout options from the results in the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Artrya Limited is a medical technology company focused on developing and commercializing an artificial intelligence platform for detecting, diagnosing, and addressing coronary artery disease in Australia, with a market cap of A$545.39 million.
Operations: The company generates revenue primarily from the development of AI-driven CCTA image analysis technology, amounting to A$0.03 million.
Artrya, despite its current unprofitable status, is demonstrating robust potential with projected annual revenue growth at 50.5% and earnings expected to surge by 61.25% per year. This growth trajectory is significantly above the Australian market average of 6% for revenue and aligns with high-growth benchmarks in tech sectors globally. Recent strategic moves include a follow-on equity offering raising AUD 75 million, underscoring their aggressive expansion plans and commitment to scaling operations. These financial maneuvers are crucial as Artrya aims to transition from a small-scale operation into a profitable entity over the next three years, leveraging advancements in MedTech and digital health solutions showcased in recent high-profile conferences like the CG MedTech Forum in New York.
ASX:AYA Earnings and Revenue Growth as at Dec 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Cogstate Limited is a neuroscience solutions company focused on developing and commercializing digital brain health assessments globally, with a market capitalization of A$435.93 million.
Operations: Cogstate Limited generates revenue primarily through its Clinical Trials segment, which includes precision recruitment tools and research, contributing $50.58 million. The Healthcare segment, encompassing sports-related assessments, adds $2.51 million to the company’s revenue stream.
Cogstate, a player in the Australian tech landscape, is charting a growth path with its revenue and earnings expanding at 13.1% and 19.1% annually, respectively—outpacing the broader Australian market averages of 6% for revenue. This performance is bolstered by significant R&D investments, which have been instrumental in driving innovation and maintaining competitive edge within the tech sector; last year alone, R&D expenses constituted a substantial portion of their operational spending. Furthermore, Cogstate’s recent strategic decision to repurchase up to 16.88 million shares underscores confidence in their financial health and future prospects, enhancing shareholder value amidst expansive market operations. These moves highlight Cogstate’s proactive approach in leveraging technological advancements to secure its position in high-growth segments while navigating through dynamic market conditions effectively.
ASX:CGS Revenue and Expenses Breakdown as at Dec 2025
Simply Wall St Growth Rating: ★★★★★☆
Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across various regions including Australia, Europe, the United States, and Switzerland with a market cap of A$618.98 million.
Operations: Clinuvel Pharmaceuticals generates revenue primarily from its biopharmaceutical sector, amounting to A$95.02 million. The company operates across multiple regions, focusing on treatments for a range of serious medical conditions.
Clinuvel Pharmaceuticals is making significant strides in the high-growth tech sector in Australia, with a notable annual revenue growth of 22% and earnings growth of 23.9%. This robust financial performance is underpinned by substantial R&D investments, which are crucial for fostering innovation and sustaining competitive advantage. At the recent Bell Potter Healthcare Conference, Clinuvel showcased its strategic focus on exploring acquisitions to bolster its market position, particularly in North America. Despite abandoning two potential deals due to stringent return requirements, the company’s disciplined capital management approach reflects a strong commitment to driving shareholder value while ensuring operational resilience and profitability.
ASX:CUV Revenue and Expenses Breakdown as at Dec 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:AYA ASX:CGS and ASX:CUV.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
